The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
if a person takes you know Crestor and Zeta and their trans Amin's pre-therapy are in the 20s and post therapy they're 50 I mean yes there's probably there's I hope there's a reason they're taking Crestor and zet and I hope that that um speaks to a risk reduction that's significant with respect to ascvd but we shouldn't conclude from that that their liver is Happy should we no
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
but we shouldn't conclude from that that their liver is Happy should we no and I think this is where we sort of get into the full differences if you're looking at a a change from 19 to 25 19 to 30 you know you're still within the range of normal I think most people would say risk benefit um favors um continuing on that on that um lipid lowering agent